Newron Pharmaceuticals S.p.A.

SWX:NWRN Stock Report

Market Cap: CHF 165.2m

Newron Pharmaceuticals Management

Management criteria checks 3/4

Newron Pharmaceuticals' CEO is Stefan Weber, appointed in Jun 2012, has a tenure of 12.5 years. total yearly compensation is €510.00K, comprised of 93.1% salary and 6.9% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth CHF172.77K. The average tenure of the management team and the board of directors is 12.5 years and 12.9 years respectively.

Key information

Stefan Weber

Chief executive officer

€510.0k

Total compensation

CEO salary percentage93.1%
CEO tenure12.5yrs
CEO ownership0.1%
Management average tenure12.5yrs
Board average tenure12.9yrs

Recent management updates

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11
Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Recent updates

Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Sep 03
Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11
Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06
We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06
Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01
Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25
A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

CEO Compensation Analysis

How has Stefan Weber's remuneration changed compared to Newron Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€19m

Mar 31 2024n/an/a

-€18m

Dec 31 2023€510k€475k

-€16m

Sep 30 2023n/an/a

-€16m

Jun 30 2023n/an/a

-€16m

Mar 31 2023n/an/a

-€17m

Dec 31 2022€498k€429k

-€17m

Sep 30 2022n/an/a

-€16m

Jun 30 2022n/an/a

-€14m

Mar 31 2022n/an/a

-€15m

Dec 31 2021€510k€414k

-€15m

Sep 30 2021n/an/a

-€17m

Jun 30 2021n/an/a

-€20m

Mar 31 2021n/an/a

-€20m

Dec 31 2020€582k€403k

-€21m

Sep 30 2020n/an/a

-€19m

Jun 30 2020n/an/a

-€17m

Mar 31 2020n/an/a

-€18m

Dec 31 2019€691k€440k

-€20m

Sep 30 2019n/an/a

-€21m

Jun 30 2019n/an/a

-€21m

Mar 31 2019n/an/a

-€18m

Dec 31 2018€647k€430k

-€15m

Sep 30 2018n/an/a

-€15m

Jun 30 2018n/an/a

-€14m

Mar 31 2018n/an/a

-€10m

Dec 31 2017€563k€418k

-€5m

Compensation vs Market: Stefan's total compensation ($USD530.20K) is below average for companies of similar size in the Swiss market ($USD874.15K).

Compensation vs Earnings: Stefan's compensation has increased whilst the company is unprofitable.

CEO

Stefan Weber (59 yo)

12.5yrs

Tenure

€510,000

Compensation

Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201...

Leadership Team

NamePositionTenureCompensationOwnership
Stefan Weber
CEO & Executive Director12.5yrs€510.00k0.10%
CHF 172.8k
Roberto Galli
Chief Financial Officer12.5yrsno data0.013%
CHF 21.2k
Filippo Moriggia
Vice President of Operations2.4yrsno datano data
Ravi Anand
Chief Medical Officer19.6yrs€1.12m0.22%
CHF 355.5k
Laura Faravelli
Vice President of Business Development1.4yrsno datano data

12.5yrs

Average Tenure

Experienced Management: NWRN's management team is seasoned and experienced (12.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stefan Weber
CEO & Executive Director12.9yrs€510.00k0.10%
CHF 172.8k
Patrick Langlois
Independent Non-Executive Director16.4yrs€78.00k0.062%
CHF 101.9k
Ulrich Köstlin
Independent Non-Executive Chairman11.7yrs€106.00k0.21%
CHF 341.7k
Luca Benatti
Non-Executive & Independent Director10.8yrs€68.00kno data
William Langston
Member of Scientific Advisory Boardno datano datano data
Ze' Seltzer
Member of Scientific & Clinical Advisory Boardno datano datano data
Fabrizio Stocchi
Member of Scientific and Clinical Advisory Boardno datano datano data
Emilio Perucca
Member of Scientific & Clinical Advisory Boardno datano datano data
Paolo Marchettini
Member of Scientific & Clinical Advisory Boardno datano datano data
Marco Onofrj
Member of Scientific Advisory Boardno datano datano data
Abraham Lieberman
Member of Scientific Advisory Boardno datano datano data
Richard Murphy
Chairman of the Board of Statutory Auditors22.9yrs€13.00kno data

12.9yrs

Average Tenure

63yo

Average Age

Experienced Board: NWRN's board of directors are seasoned and experienced ( 12.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 14:30
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research